Purpose: Radioiodine (131I) thyroid remnant ablation is an important treatment of
differentiated thyroid carcinoma (DTC) and various factors affecting its efficacy have been …

Recommended treatment for most patients with differentiated thyroid cancer is surgery
followed by radioiodine ablation. Current practice in many centres is to use a high …

Low‐risk (LR) differentiated thyroid cancer (DTC) patients should be ablated or not, albeit,
with small dose of radioiodine is highly controversial. We hypothesized that those LR DTC …

Context: There is uncertainty over the dose of 131I required for thyroid remnant ablation.
Most previous studies have been inadequately powered to establish the best fixed dose of …

[en] This study was performed under the auspices of IAEA project (i) to evaluate the efficacy
of low (50 mCi) vs. high (100 mCi) dose I-131 for post operative remnant ablation in …

Recently an editorial by Hay et al. was published in the Journal of Nuclear Medicine
favouring abolishing the use of postoperative radioiodine ablation of thyroid remnant tissue …

The main steps in the management of differentiated thyroid cancer are thyroidectomy,
treatment with iodine-131 (131I), and follow-up with whole-body scanning (WBS) and serum …

Radioactive iodine therapy is administered to patients with differentiated thyroid cancer
(DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with …

Background: Radioiodine (131I) remnant ablation (RRA) has become a key step in the
postoperative treatment of differentiated thyroid cancer (DTC). However, inadequate or …

Background The aim of this study is to compare the effectiveness of 131 I therapy between
three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation …